Krystexxa
Payments companies reported to CMS as associated with Krystexxa. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Krystexxa, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Krystexxa
These are the largest totals companies reported as associated with Krystexxa. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| John Cozzarelli | Belleville, NJ | Foot & Ankle Surgery | $461,744.65 |
| Mark Spier | Glen Burnie, MD | Foot & Ankle Surgery | $329,945.06 |
| John Botson | Anchorage, AK | Rheumatology | $328,632.81 |
| Namrata Goel | Houston, TX | Nephrology (Internal Medicine) | $312,892.23 |
| Jeff Peterson | Bothell, WA | Rheumatology | $308,687.34 |
| Abdul Abdellatif | Webster, TX | Nephrology (Internal Medicine) | $290,418.56 |
| Roman Czubatyj | Rochester Hills, MI | Rheumatology | $267,221.44 |
| Sunil Patel | Apple Valley, CA | Nephrology (Internal Medicine) | $254,225.84 |
| Jigar Shah | Margate, FL | Rheumatology | $229,166.98 |
| Edmund Maclaughlin | Easton, MD | Rheumatology | $229,140.86 |
Prescribed Krystexxa?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.